|
The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Tuesday. ---------- FTSE 100 winners ---------- Metlen Energy & Metals PLC, up 3.1% at €41.16 Bunzl PLC, up 2.9% at 2,566.00 pence, Exane BNP raises to ’outperform’ Persimmon PLC, up 2.2% at 1,064.50p, housebuilders rebound after falling on Monday Croda International PLC, up 2.4% at 2,931.00p, Deutsche Bank Research ups price target Barratt Redrow PLC, up 2.1% at 258.65p ---------- FTSE 100 losers ---------- GSK PLC, down 3.4% at 1,847.50p, agrees to buy US cancer drug maker Nuvalent BT Group PLC, down 2.1% at 200.20p Glencore PLC, down 2.0% at 583.00p Sage Group PLC, down 2.0% at 845.20p AstraZeneca PLC, down 1.8% at 13,543.00p, progresses weight-loss drug after positive results ---------- FTSE 250 winners ---------- Molten Ventures PLC, up 11% at 595.25p, reports sharp rise in ICEYE valuation Breedon Group PLC, up 4.9% at 288.80p, completes Falling Springs Quarry acquisition WPP Group PLC, up 4.8% at 274.65p, Berenberg starts coverage with ’buy’ rating Keller Group PLC, up 3.6% at 2,553.00p, secures multi-year I-40 highway contract variation Marshalls PLC, up 3.4% at 134.40p ---------- FTSE 250 losers ---------- Oxford Instruments PLC, down 6.9% at 2,873.00p, profit up but first half sales fall Ithaca Energy PLC, down 2.9% at 248.40p, tracks oil price lower Genus PLC, down 2.4% at 2,183.00p Raspberry Pi Holdings PLC, down 2.2% at 1,017.50p AEP Plantations PLC, down 2.1% at 1,502.00p ---------- FTSE 100 & 250 movers in focus: ---------- GSK PLC, down 3.4% at 1,847.50p, 12-month range 1,288.60p-2,282.00p. Shares fall after GSK makes its largest acquisition in over a decade. The London-based pharmaceutical firm says it has agreed to buy oncology-focused biopharmaceutical company Nuvalent for $10.6 billion. The acquisition includes three products in lung cancer, GSK notes. Zidesamtinib and neladalkib are two late-stage, potential best-in-class drugs for the treatment of lung cancer. Subject to FDA approval, they are expected to launch in 2026 with ‘multi-blockbuster potential’. GSK says the deal to buy the Boston, Massachusetts-based firm is ‘consistent’ with its strategy of ‘acquiring assets that have validated targets and meaningfully address efficacy and/or tolerability limitations of existing standard-of-care therapies’. GSK will start a tender offer to acquire all of Nuvalent’s outstanding shares at $124 per share in cash within 10 business days. ---------- Bunzl PLC, up 2.9% at 2,566.00 pence, 12-month range 1,981.00p-2,609.42p. Exane BNP raises its rating for the distribution and services company to ’outperform’ from ’neutral’. It increases the price target for the stock to 3,000p from 2,450p. ---------- Molten Ventures PLC, up 11% at 595.25p, 12-month range 284.00p-606.00p. The backer of digital technology businesses as it says its holding value in ICEYE will increase to £317 million, representing an uplift of £238 million from the holding value at the end of March. This comes as ICEYE, a provider of sovereign intelligence from space, raises around €450 million in a primary Series F funding round. As part of the funding round, Molten has realised a further £22 million of its investment in the company. It sees this uplift boosting Molten’s gross portfolio value by 16% and NAV per share by 15% to 877p from 760p. Separately, Molten says in its full-year results that NAV per share rose to 760p at the end of March from 671p a year earlier. Seraphim Space Investment Trust PLC, also a holder of ICEYE, rises 14%. ---------- Breedon Group PLC, up 4.9% at 288.80p, 12-month range 271.40p-462.60p. The Derby, England-based construction materials firm completes the acquisition of Falling Springs Quarry, located near St Louis, Missouri, for an enterprise value of $120 million. The limestone quarry has an output of over 2.2 million tonnes per year. Breedon expects the transaction to be immediately margin and earnings enhancing. ---------- Oxford Instruments PLC, down 6.9% at 2,873.00p, 12-month range 1,682.00p-3,318.00p. The Buckinghamshire, England-based high-technology instruments company says it remains confident in its mid-term goals but reports lower revenue. It says pretax profit climbs 53% to £58.5 million in the financial year that ended March 31 from £38.2 million the year prior, despite a 4.6% decline in revenue to £423.2 million from £443.4 million. Oxford Instruments took a £26.0 million impairment of goodwill in financial 2025, versus no such charge in the recent year. ‘Whilst the macroeconomic and geopolitical environment remains uncertain, we are making clear progress against the strategy set out in 2024 and remain well positioned in structurally growing markets,’ Chief Executive Richard Tyson says. ---------- Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
